CyberHeart Takes Non-invasive Approach To AF Ablation

CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. Current clinical trials are examining the use of CyberHeart not only for atrial fibrillation (AF) treatment, but also for ventricular tachycardia, for which a US pivotal trial is scheduled for early 2017.

Catheter-based atrial fibrillation (AF) ablation procedures have spared countless patients from open-heart surgery, and companies continue to improve on that technology. ([A#MT103609]) But an entirely non-invasive ablation option could soon be available. CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. The treatment requires no anesthesia, and patients go home the same day.

Patrick Maguire, MD, PhD, a cardiac surgeon who once performed open AF ablation or maze procedures, is president and CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Startups & SMEs

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from Business

Veterinary Heart Health Goes High-Tech: Eko And Boehringer Use AI To Spot Heart Murmurs In Dogs

 
• By 

Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Ellipsis Raises $45M To Expand AI Care Manager Across Health Systems

 
• By 

Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.